Synchronous and metachronous neoplasms in gastric cancer patients: A 23-year study

Table 1 Comparison of clinicopathological features of gastric cancer patients with and without a second primary cancer n (%)

Characteristic	Total	Gastric cancer	Multiple gastric cancer	P value
Gender				0.499
Male	570 (66.1)	534 (66.4)	36 (62.1)
Female	292 (33.9)	270 (33.6)	22 (37.9)
Total	862	804	58
Age1 (yr)	59.8 ± 12.8	59.5 ± 13.0	63.4 ± 11.4	0.026
DS (mo)	25.1 ± 46.4	25.1 ± 46.5	26.3 ± 46.3	0.433
FHC				0.806
No	369 (52.6)	342 (52.7)	27 (50.9)
Yes	333 (47.4)	307 (47.3)	26 (49.1)
Total	702
Location2				0.467
Proximal	181 (21)	171 (21.3)	10 (17.2)
Other location	681 (79)	633 (78.7)	48 (82.8)
Total	862
Histology				0.116
Intestinal	260 (43.4)	234 (42.2)	26 (57.8)
Diffuse	289 (48.3)	272 (49.1)	17 (37.8)
Mixed	50 (8.3)	48 (8.7)	2 (4.4)
Total	599
Stage				0.100
Early	119 (16.4)	106 (15.7)	13 (24.5)
Advanced	608 (83.6)	568 (84.3)	40 (75.5)
Total	727
Blood group				0.002
A	211 (37.2)	198 (38.1)	13 (27.1)
B	106 (18.7)	98 (18.9)	8 (16.7)
O	191 (33.7)	164 (31.6)	27 (56.2)
AB	59 (10.4)	59 (11.4)	None
Total	567

¹Data are expressed as mean ± SD;

²Tumor location. DS: Duration of symptoms; FHC: Family history of cancer.

Table 2 Comparision of the clinicopathological features of gastric cancer patients with metachronous and synchronous tumors n (%)

Characteristic	Total	Metachronous	Synchronous	P value
Gender				0.139
Male	34	18 (52.9)	16 (72.7)
Female	22	16 (47.1)	6 (27.3)
Total1	56	34	22
Age2 (yr)	63.1 ± 11.3	59.9 ± 11.1	68.0 ± 10.3	0.008
DS (mo)	27.3 ± 46.9	31.7 ± 44.0	22.1 ± 54.0	0.217
FHC				0.249
No	26	14 (53.8)	12 (46.2)
Yes	25	18 (72.0)	7 (28.0)
Total	51
Location3				0.724
Proximal	10	7 (70.0)	3 (30.0)
Other location	46	27 (58.7)	19 (41.3)
Total	56
Histology				0.835
Intestinal	24	16 (66.7)	8 (33.3)
Diffuse	17	12 (70.6)	5 (29.4)
Mixed	2	1 (50.0)	1 (50.0)
Total	43
Stage				0.553
Early	13	7 (53.8)	6 (46.2)
Advanced	38	24 (63.2)	14 (36.8)
Total	51
Blood group				0.675
A	13	9 (69.2)	4 (30.8)
B	8	4 (50.0)	4 (50.0)
O	25	15 (60.0)	10 (40.0)
AB	None	None	None
Total	46

¹Two patients were excluded from this comparison because they developed both metachronous and synchronous cancers;

²Data are expressed as mean ± SD;

³Tumor location. DS: Duration of symptoms; FHC: Family history of cancer.

Table 3 Sites of additional synchronous and metachronous cancers in gastric cancer patients n (%)

Site	No. tumors	Metachronous	Synchronous
	n = 62	n = 39	n = 23
Colorectal	17 (27.4)	7 (17.9)	10 (43.5)
Lung	9 (14.5)	5 (12.8)	4 (17.4)
Breast	8 (12.9)	7 (17.9)	1 (4.3)
Prostate	7 (11.3)	4 (10.3)	3 (13.1)
Lymphoma	4 (6.5)	2 (5.1)	2 (8.7)
Skin	4 (6.5)	2 (5.1)	2 (8.7)
Urinary bladder	3 (4.9)	3 (7.7)	-
Kidney	2 (3.2)	1 (2.6)	1 (4.3)
Larynx	2 (3.2)	2 (5.1)	-
Non Hodgkin Lymphoma	2 (3.2)	2 (5.1)	-
Head	1 (1.6)	1 (2.6)	-
Ovary	1 (1.6)	1 (2.6)	-
Pancreas	1 (1.6)	1 (2.6)	-
Uterus	1 (1.6)	1 (2.6)	-